Published in Cancer Weekly, November 19th, 2002
As a result, Cell Genesys now holds all worldwide commercial rights to its entire portfolio of GVAX cancer vaccine products.
Given the scope of the company's plans for the next clinical trials of GVAX lung cancer vaccine, as well as the anticipated funding from the U.S. National Cancer Institute for one of those trials, Cell Genesys expects the near-term revenue impact from ending the agreement with JT to be...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.